Investors

Stock
Information

MEDINCELL EURONEXT ELIGIBLE PME PEA

Listed on
EURONEXT PARIS / B COMPARTMENT
ISIN code / Ticker
FR0004065605 / MEDCL
Number of shares (June 30, 2023)
28,718,045
Liquidity Provider
KEPLER CHEUVREUX
Analysts
BRYAN GARNIER & CO
KEPLER CHEUVREUX
ODDO-BHF
TP ICAP
PORTZAMPARC-BNP PARIBAS GROUP
JEFFERIES

Download our latest corporate presentation

Share price 27.02.2024 | 17:29 (Paris time)
9.12 €1.33%
Opening8.94 €
Previous closing 9.0 €
Shares traded 28.09 k

Investors

Events &
Presentations

June 25, 2024

Annual results 2023-2024 (Apr. 2023 > Mar. 2024)

September 12, 2024

2024 General Meeting

December 10, 2024

Half-Year results (Apr. > Sept. 2024)

PREVIOUS EVENTS

December 19, 2023

Video conference Half Year results 2023-24

Replay

Presentation

September 12, 2023

2023 General Meeting (in French)

Replay

June 26, 2023

Video conference annual results 2022-23

Replay

Transcript Presentation

May 02, 2023

Video conference • Approval of UZEDY™

Replay

Transcript

December 06, 2022

Video conference Half Year results

Replay

Transcript Presentation

September 08, 2022

General Meeting (French)

Replay

September 05, 2022

Videoconference • General meeting preparation (French)

Replay

June 14, 2022

Videoconference • Annual results 2021-202

Replay

Transcript Presentation

December 08, 2021

Videoconference • Half Year results

Replay

Transcript Presentation

November 02, 2021

Videoconference • mdc-IRM Phase 3 results

Replay

Transcript

September 01, 2021

Video conference • Portfolio update

Replay

Transcript Presentation

June 16, 2021

Video Conference • Annual results

Replay

Transcript Presentation

December 09, 2020

Video Conference • Half year results

Replay

Transcript

June 04, 2020

Video Conference • Annual results

Replay

Transcript

April 23, 2020

Video Conference • Adapt and overcome to the Covid-19 crisis

Replay

Transcript Presentation

December 03, 2019

Audio conference • Half year results

Replay

Transcript Presentation

June 04, 2019

Audio Conference • Annual results

Replay

Transcript Presentation

December 03, 2018

Audio Conference • Half year results

Replay

Transcript Presentation

Investors

Regulated informations

Shares & Voting rights

October 31, 2023 (French)

September 30, 2023 (French)

August 31, 2023 (French)

See all

July 31, 2023 (French)

June 30, 2023 (French)

May 31, 2023 (French)

April 30, 2023 (French)

March 31, 2023 (French)

February 28, 2023 (French)

January 31, 2023 (French)

December 31, 2022 (French)

November 30, 2022 (French)

October 31, 2022 (French)

September 30, 2022 (French)

August 31, 2022 (French)

July 31, 2022 (French)

June 30, 2022 (French)

May 31, 2022 (French)

April 30, 2022 (French)

March 31, 2022 (French)

February 28, 2022 (French)

January 31, 2022 (French)

December 31, 2021 (French)

November 30, 2021 (French)

October 31, 2021 (French)

September 30, 2021 (French)

August 31, 2021 (French)

July 31, 2021 (French)

May 31, 2021 (French)

April 30, 2021 (French)

March 31, 2021 (French)

February 28, 2021 (French)

January 31, 2021 (French)

December 31, 2020 (French)

October 31, 2020 (French)

September 30, 2020 (French)

August 31, 2020 (French)

July 31, 2020 (French)

June 30, 2021 (French)

June 30, 2020 (French)

May 31, 2020 (French)

Avril 30, 2020 (French)

March 31, 2020 (French)

February 29, 2020 (French)

January 31, 2020 (French)

December 31, 2019 (French)

November 30, 2019 (French)

October 31, 2019 (French)

September 30, 2019 (French)

August 31, 2019 (French)

July, 31, 2019 (French)

June 30, 2019 (French)

May 31, 2019 (French)

April 30, 2019 (French)

March 31, 2019 (French)

February 28, 2019 (French)

January 31, 2019 (French)

December 31, 2018 (French)

November 30, 2018 (French)

October 31, 2018 (French)

Investors

General
Meeting

September 2023
September 2022
September 2021
September 2020
December 2020
September 2019

September 2023

> Voting results (French) > Text of resolutions > Voting form > URD 2022-2023 > Notice brochure (French) > Report of the Supervisory Board to the annual ordinary and extraordinary general meeting of September 12, 2023 (French) > Notice of meeting (French) > Report of the Management Board to the ordinary and extraordinary general meeting of September 12, 2023 (French) > Statement by the statutory auditors on the information communicated within the framework of article L.225-115 5° of the commercial code relating to the total amount of payments made pursuant to 1 to 5 of article 238 bis of the general code of taxes for the year ended March 31, 2023 > Statement by the Statutory Auditors on the information communicated in the context of Article L. 225-115 4° of the French Commercial Code relating to the total amount of compensation paid to the highest-paid persons for the financial year ended March 31, 2023 (French) > Report of the Statutory Auditors on the issue of shares and various securities with maintenance and/or cancellation of preferential subscription rights > Report of the Statutory Auditors on the authorization to allocate free shares existing or to be issued (French) > Report of the Statutory Auditors on the capital increase reserved for members of a company savings plan > Report of the Statutory Auditors on the authorization to grant share subscription and/or purchase options (French) > Report of the Statutory Auditors on the issue of stock warrants with cancellation of the preferential subscription right (French) > Report of the Statutory Auditors on the modification of the terms and conditions of the stock warrants issued by the Chairman of the Management Board on December 21, 2022 (the ‘BSA BEI 1’), on January 11, 2023 (the ‘BSA BEI 2’) and July 31, 2023 (the ‘BSA BEI 3’) (French) > Report of the statutory auditors on the capital reduction (French) > Voting rights as of August 4, 2023 (French)

See all

Investors

Contacts

MedinCell

Head of Communication / IR

David Heuzé

david.heuze@medincell.com

+33 (0)6 83 25 21 86

MedinCell

Senior Communications Officer

Nicolas Gourgues

nicolas.gourgues@medincell.com

Investor Relations

NewCap

Louis-Victor Delouvrier & Alban Dufumier

medincell@newcap.eu

+33 (0)1 44 71 94 94

Media

NewCap

Nicolas Merigeau

medincell@newcap.eu

+33 (0)1 44 71 94 94

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.